These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31186530)

  • 1. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].
    Lax S
    Pathologe; 2011 Nov; 32 Suppl 2():255-64. PubMed ID: 22033684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical Endometrial Hyperplasia, Low-grade: "Much ADO About Nothing".
    D'Angelo E; Espinosa I; Cipriani V; Szafranska J; Barbareschi M; Prat J
    Am J Surg Pathol; 2021 Jul; 45(7):988-996. PubMed ID: 34105519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
    Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
    Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
    Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
    Li L; Yue P; Song Q; Yen TT; Asaka S; Wang TL; Beavis AL; Fader AN; Jiao Y; Yuan G; Shih IM; Song Y
    J Pathol; 2021 Jan; 253(1):119-128. PubMed ID: 33016334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability.
    Hardisson D; Moreno-Bueno G; Sánchez L; Sarrió D; Suárez A; Calero F; Palacios J
    Mod Pathol; 2003 Nov; 16(11):1148-58. PubMed ID: 14614055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
    Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
    Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
    Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Ta RM; Hecht JL; Lin DI
    Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
    Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
    Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated histological parameters define prognostically relevant groups in atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia.
    Raffone A; Insabato L; Raimondo D; Del Piano I; Ricciardiello M; Cretella P; Neola D; Arciuolo D; Santoro A; Seracchioli R; Guida M; Travaglino A; Zannoni GF
    Int J Gynecol Cancer; 2024 Aug; 34(8):1183-1188. PubMed ID: 38719279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia.
    Horowitz N; Pinto K; Mutch DG; Herzog TJ; Rader JS; Gibb R; Bocker-Edmonston T; Goodfellow PJ
    Gynecol Oncol; 2002 Jul; 86(1):62-8. PubMed ID: 12079302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiles of benign and (pre)malignant endometrial lesions.
    van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
    Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.